

Michael Newton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7970631/publications.pdf>

Version: 2024-02-01

17
papers

980
citations

1478505

6
h-index

1199594

12
g-index

18
all docs

18
docs citations

18
times ranked

815
citing authors

#	ARTICLE	IF	CITATIONS
1	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	1.6	445
2	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. <i>Lung Cancer</i> , 2022, 166, 84-93.	2.0	7
3	Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8511-8511.	1.6	74
4	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—An Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 860-867.	1.1	323
5	Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). <i>Clinical Lung Cancer</i> , 2021, 22, 549-561.	2.6	25
6	Impact of Cognitive and Social Factors on Smoking Cessation Attempts among US Adult Muslim Smokers. <i>Innovations in Pharmacy</i> , 2020, 11, .	0.6	0
7	Tobacco Use among Adult Muslims in the United States. <i>Substance Use and Misuse</i> , 2019, 54, 1385-1399.	1.4	6
8	Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 186-200.	4.4	80
9	Oral Antineoplastic Agents: Assessing the Delay in Care. <i>Chemotherapy Research and Practice</i> , 2015, 2015, 1-4.	1.6	4
10	Assessing the impact of a targeted electronic medical record intervention on the use of growth factor in cancer patients. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 113-116.	0.1	5
11	Successful rechallenge after ixabepilone-induced radiation recall dermatitis using an alternative dosing strategy. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 89-92.	0.9	5
12	Surviving in a cofunded faculty appointment. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 102-104.	1.0	1
13	mTOR as a target in breast cancer: the emerging role of everolimus. <i>Breast Cancer Management</i> , 2012, 1, 47-56.	0.2	0
14	Does Antimicrobial Stewardship Begin at the Dinner Table?. <i>Clinical Infectious Diseases</i> , 2011, 53, 402-403.	5.8	0
15	Topoisomerase I Inhibitors — The Camptothecins. , 2011, , 103-123.		1
16	Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan. <i>Journal of Oncology</i> , 2008, 2008, 1-4.	1.3	4
17	Licorice. , 0, , 223-235.		0